---
document_datetime: 2023-09-21 19:24:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_en.pdf
document_name: incruse-ellipta-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8280412
conversion_datetime: 2025-12-19 06:01:45.980911
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form               | Route of Administration   | Immediate Packaging   | Pack size                             |
|------------------|-------------------|------------|-----------------------------------|---------------------------|-----------------------|---------------------------------------|
| EU/1/14/922/001  | Incruse Ellipta   | 55 µg      | Inhalation powder, pre- dispensed | Inhalation use            | Blister (alu)         | 1 inhaler (7 doses)                   |
| EU/1/14/922/002  | Incruse Ellipta   | 55 µg      | Inhalation powder, pre- dispensed | Inhalation use            | Blister (alu)         | 1 inhaler (30 doses)                  |
| EU/1/14/922/003  | Incruse Ellipta   | 55 µg      | Inhalation powder, pre- dispensed | Inhalation use            | Blister (alu)         | 3 inhalers (3 x 30 doses) (multipack) |